Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics

Journal of Medicinal Chemistry

Volumn 45, Issue 20, 2002, Pages 4419-4432

  Adang, Anton E P ^a   De Man, Adrianus P A ^a   Vogel, Gerard M T ^a   Grootenhuis, Peter D J ^b   Smit, Martin J ^a   Peters, Co A M ^a   Visser, Arie ^a   Rewinkel, Jos B M ^a   Van Dinther, Theo ^a   Lucas, Hans ^a   Kelder, Jan ^a   Van Aelst, Sjoerd ^a   Meuleman, Dick G ^a   Van Boeckel, Constant A A ^a  

^a NV ORGANON   (Netherlands)

^b DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LISINOPRIL; THROMBIN; THROMBIN INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; HYDROPHILICITY; HYDROPHOBICITY; NONHUMAN; RAT; X RAY ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; AORTA; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CRYSTALLOGRAPHY, X-RAY; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FIBRINOLYTIC AGENTS; HALF-LIFE; HUMANS; MODELS, MOLECULAR; OLIGOPEPTIDES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN; THROMBOSIS;

EID: 0037179611     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm011110z     Document Type: Article

References (50)

1. Burnier, M.; Brunner, H. R. Angiotensin II AT1 receptor antagonists: clinical development and future perspectives. Therapie 1998, 53, 279-284.
2. Freidinger, R. M. Nonpeptide ligands for peptide and protein receptors. Curr. Opin. Chem. Biol. 1999, 3, 395-406.
3. De Tullio, P.; Delarge, J.; Pirotte, B. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists). Curr. Med. Chem. 1999, 6, 433-455.
4. Burrell, L. M.; Risvanis, J.; Johnston, C. I.; Naitoh, M.; Balding, L. C. Vasopressin receptor antagonism-a therapeutic option in heart failure and hypertension. Exp. Physiol. 2000, 85, 259S-265S.
5. Owens, M. J.; Nemeroff, C. B. Corticotropin-releasing factor antagonists in affective disorders. Exp. Opin. Invest. Drugs 1999, 8, 1849-1858.
6. Veale, C. A.; Damewood, J. R., Jr.; Steelman, G. B.; Bryant, C.; Gomes, B.; Williams, J. Non-peptide inhibitors of human leukocyte elastase. 4. Design, synthesis, and in vitro and in vivo activity of a series of beta-carbolinone-containing trifluoromethyl ketones. J. Med. Chem. 1995, 38, 86-97.
7. Luther, R. R.; Stein, H. H.; Glassman, H. N.; Kleinert, H. D. Renin inhibitors: specific modulators of the renin-angiotensin system. Arzneim.-Forsch. 1989, 39, 1-5.
8. Weitz, J. I.; Hirsh, J. New antithrombotic agents. Chest 1998, 114, 715S-727S.
9. Turpie, A. G. Clinical potential of antithrombotic drugs in coronary syndromes. Am. J. Cardiol. 1998, 82, 11L-14L.
10. Wiley, M.; Fisher, M. J. Small-molecule direct thrombin inhibitors. Exp. Opin. Ther. Pat. 1997, 7, 1265-1282.
11. Rewinkel, J. B. M.; Adang, A. E. P. Strategies and progress towards the ideal orally active thrombin inhibitor. Curr. Pharm. Des. 1999, 5, 1043-1075.
12. Adang, A. E. P.; Rewinkel, J. B. M. A new generation of orally active antithrombotics: comparing strategies in the GPIIb/IIIa, thrombin and factor Xa areas. Drugs Future 2000, 25, 369-383.
13. 1 moiety. Bioorg. Med. Chem. Lett. 1998, 8, 3603-3608.
14. Rewinkel, J. B. M.; Lucas, H.; van Galen, P. J. M. 1-Aminoisoquinoline as benzamidine isoster in the design and synthesis of orally active thrombin inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 685-690.
15. Adang, A. E. P.; Peters, C. A. M.; Gerritsma, S.; de Zwart, E.; Veeneman, G. Solution-phase and solid-phase synthesis of novel transition state inhibitors of coagulation enzymes incorporating a piperidinyl moiety. Bioorg. Med. Chem. Lett. 1999, 9, 1227-1232.
16. Brady, S. F.; Sisko, J. T.; Stauffer, K. J.; Colton, C. D.; Qiu, H.; Lewis, S. D.; Ng, A. S.; Shafer, J. A.; Bogusky, M. J.; Veber, D. F.; Nutt, R. F. Amide and a-keto carbonyl inhibitors of thrombin based on arginine and lysine: synthesis, stability and biological characterization. Bioorg. Med. Chem. 1995, 3, 1063-1078.
17. Jones, D. M.; Atrash, B.; Ryder, H.; Teger-Nilsson, A.-C.; Gyzander, E.; Szelke, M. Thrombin inhibitors based on ketone derivatives of arginine and lysine. J. Enzyme Inhib. 1995, 9, 43-60.
18. Bajusz, S.; Szell, E.; Bagdy, D.; Barabas, E.; Horvath, G.; Dioszegi, M.; Fittler, Z.; Szabo, G.; Juhasz, A. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D.-MePhe-Pro-Arg-H. J. Med. Chem. 1990, 33, 1729-1735.
19. Gallemo, R. A., Jr.; Fevig, J. M.; Carini, D. J.; Cacciola, J.; Wells, B. L.; Hillyer, G. L.; Buriak, J., Jr.; Rossi, K. A.; Stouten, P. F. W.; Alexander, R. S.; Hilmer, R.; Bostrom, L.; Abelman, M. M.; Lee, S.-L.; Weber, P. C.; Kettner, C. A.; Knabb, R. M.; Wexler, R. R. (Nacyl-N-alkyl)glycyl borolysine analogues: new class of potent thrombin inhibitors. Bioorg. Med. Chem. Lett. 1996, 6, 2913-2918.
20. Lewis, S. D.; Ng, A. S.; Baldwin, J. J.; Fusetani, N.; Naylor, A. M.; Shafer, J. A. Inhibition of thrombin and other trypsin-like serine proteinases by cyclotheonamide A. Thromb. Res. 1991, 70, 173-190.
21. Jetten, M.; Peters, C. A. M.; Visser, A.; Grootenhuis, P. D. J.; van Nispen, J. W. F. M.; Ottenheijm, H. C. J. Peptide-derived transition state analogue inhibitors of thrombin; synthesis, activity and selectivity. Bioorg. Med. Chem. 1995, 3, 1099-1114.
22. Dondoni, A.; Perrone, D.; Merino, P. Chelation- and nonchelation-controlled addition of 2-(trimethylsilyl)thiazole to α-amino aldehydes: stereoselective synthesis of the β-amino-α-hydroxy aldehyde intermediate for the preparation of the human immunodeficiency virus proteinase inhibitor Ro 31-8959. J. Org. Chem. 1995, 60, 8074-8080.
23. Nahm, S.; Weinreb, S. M. N-methoxy-N-methylamides as effective acylating agents. Tetrahedron Lett. 1981, 22, 3815-3818.
24. Nielsen, D. G. Imidates including cyclic imidates. In The Chemistry of Amidines and Imidates; Patai, S., Ed.; John Wiley & Sons: New York, 1975; Vol. I, pp 385-489.
25. 125I oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones. J. Org. Chem. 1983, 48, 4155-4156.
26. 1′ subsite: Tripeptide transition state analogues based on a heterocycle-activated carbonyl group. J. Med. Chem. 1996, 39, 3039-3043.
27. 1′ binding site. Biophys. J. 1996, 71, 2830-2839.
28. Kaiser, B.; Hauptmann, J.; Weiss, A.; Markwardt, F. Pharmacological characterization of a new highly effective synthetic thrombin inhibitor. Biomed. Biochim. Acta 1985, 44, 1201-1210.
29. Adang, A. E. P.; Van Boeckel, C. A. A.; Grootenhuis, P. D. J.; Peters, J. A. M. WO 9717363, 1997.
30. Van Boeckel, C. A. A.; Adang, A. E. P.; Peters, J. A. M. WO 9807308, 1998.
31. Lewis, S. D.; Ng, E. A.; Mellott, M. J.; Appleby, S. D.; Brady, S. F.; Stauffer, K. J.; Sisko, J. T.; Mao, S. S.; Veber, D. F. Inhibition of thrombin by peptides containing lysyl-alpha-keto carbonyl derivatives. Thromb. Haemostasis 1995, 74, 1107-1112.
32. 1-argininoyl heterocycles. Bioorg. Med. Chem. Lett. 1997, 7, 1359-1364.
33. Akiyama, Y.; Tsutsumi, S.; Hatsushiba, E.; Ohuchi, S.; Okonogi, T. Peptidyl α-keto thiazole as potent thrombin inhibitors. Bioorg. Med. Chem. Lett. 1997, 7, 533-538.
34. 1-ketoargininamide derivatives: A novel class of serine protease inhibitors. Bioorg. Med. Chem. Lett. 1997, 7, 315-320.
35. Boatman, P. D.; Ogbu, C. O.; Eguchi, M.; Kim, H.-O.; Nakanishi, B. C.; Shea, J. P.; Kahn, M. Secondary structure peptide mimetics: Design, synthesis, and evaluation of β-strand mimetic thrombin inhibitors. J. Med. Chem. 1999, 42, 1367-1375.
36. 1′ β-strand mimetic inhibitors of thrombin. J. Med. Chem. 1999, 42, 1376-1383.
37. Bachand, B.; DiMaio, J.; Siddiqui, M. A. Synthesis and structure-activity relationship of potent bicyclic lactam thrombin inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 913-918.
38. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
39. Lee, V. H. L. Membrane transporters. J. Pharm. Sci. 2000, 11, S41-S50.
40. Ranadive, S. A.; Chen, A. X.; Serajuddin, A. T. M. Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzmyme (ACE) inhibitors. Pharm. Res. 1992, 9, 1480-1486.
41. Thwaites, D. T.; Cavet, M.; Hirst, B. H.; Simmons, N. L. Angiotensin-converting enzyme (ACE) inhibitor transport in human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol. 1995, 114, 981-986.
42. Jetten, M.; Peters, C. A. M.; van Nispen, J. W. F. M.; Ottenheijm, H. C. J. A one-pot N-protection of f L-Arginine. Tetrahedron Lett. 1991, 32, 6025-6028.
43. Edwards, P. D.; Wolanin, D. J.; Andisik, D. W.; Davis, M. W. Peptidyl a-ketoheterocyclic inhibitors of human neutrophil eleastase. 2. Effect of varying the heterocyclic ring on in vitro potency. J. Med. Chem. 1995, 38, 76-85.
44. Walter, E.; Kissel, T.; Raddatz, P. Transport of peptidomimetic renin inhibitors across monolayers of a human intestinal cell line (Caco-2): evidence for self-enhancement of paracellular transport route. Pharm. Res. 1995, 12, 1801-1805.
45. Teien, A. N.; Lie, M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb. Res. 1977, 10, 399-410.
46. Vogel, G. M. T.; van Amsterdam, R. G. M.; Zandberg, P.; van Houwelingen, P.; Kop, W. J.; van Mensvoort, F. W. J.; Meuleman, D. G. Two new closely related rat models with relevance to arterial thrombosis-efficacies of different antithrombotic drugs. Thromb. Haemostasis 1997, 77, 183-189.
47. Riboldi-Tunnicliffe, A.; Hilgenfeld, R. Cryocrystallography with oil - an old idea revived. J. Appl. Crystallogr. 1999, 32, 1003-1005.
48. Kissinger, C. R.; Gehlhaar, D. K.; Fogel, D. B. Rapid automated molecular replacement by evolutionary search. Acta Crystallogr. D 1999, 55, 484-491.
49. Bush, L. R. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc. Drug Rev. 1991, 9, 247-263.
50. Gustafsson, D.; Antonsson, T.; Bylund, R.; Eriksson, U.; Gyzander, E.; Nilsson, I.; Elg, M.; Mattsson, C.; Deinum, J.; Pehrsson, S.; Karlsson, O.; Nilsson, A.; Sörensen, H. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb. Haemostasis 1998, 79, 110-118.